Page 4 - Codexis Inc News Today

StockNews.com upgraded shares of Codexis (NASDAQ:CDXS – Free Report) to a sell rating in a research report released on Wednesday. Other analysts also recently issued research reports about the company. Piper Sandler reduced their price objective on Codexis from $14.00 to $10.00 and set an overweight rating for the company in a research report on […]

Investment Analysts’ upgrades for Wednesday, January 10th: Antero Midstream (NYSE:AM) was upgraded by analysts at StockNews.com from a hold rating to a buy rating. AMETEK (NYSE:AME) was upgraded by analysts at StockNews.com from a hold rating to a buy rating. American Tower (NYSE:AMT) was upgraded by analysts at StockNews.com from a hold rating to a […]

On December 1, 2023, Baillie Gifford (Trades, Portfolio), a renowned investment management firm, made a significant adjustment to its investment portfolio by reducing its stake in Codexis Inc (NASDAQ:CDXS). Following this transaction, Baillie Gifford (Trades, Portfolio)'s remaining holding in Codexis Inc totals 3,419,093 shares, which represents a 4.90% ownership in the company and a 0.01% position in Baillie Gifford (Trades, Portfolio)'s portfolio.

/PRNewswire/ -- The "Global Synthetic Biology Market: Analysis By Product Type, By Technology, By Application, By End Users, By Region, Size and Trends with...

Trellus Management Company LLC decreased its position in shares of Codexis, Inc. (NASDAQ:CDXS – Free Report) by 12.5% during the third quarter, HoldingsChannel reports. The firm owned 220,000 shares of the biotechnology company’s stock after selling 31,460 shares during the period. Trellus Management Company LLC’s holdings in Codexis were worth $416,000 at the end of […]

Stock analysts at Cantor Fitzgerald assumed coverage on shares of Codexis (NASDAQ:CDXS – Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $11.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 225.44% from the stock’s […]

Item 1.01. Entry into a Material Definitive Agreement. ...

REDWOOD CITY, Calif., Dec. 27, 2023 -- Codexis, Inc. , a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally...

Codexis, Inc. (NASDAQ: CDXS) entered a purchase deal with Nestlé S.A.(OTC: NSRGY) Nestlé Health Science for CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). 

(RTTNews) - Enzyme engineering company Codexis, Inc. (CDXS) announced Wednesday it has entered into a purchase agreement with Nestle Health Scienc...